U.S. markets closed

Hemogenyx Pharmaceuticals Plc (HEMO.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
2.2500+0.0750 (+3.45%)
At close: 5:06PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.1750
Open2.1500
Bid2.1500 x 0
Ask2.2500 x 0
Day's Range2.1500 - 2.2500
52 Week Range0.0650 - 15.4000
Volume4,407,830
Avg. Volume10,065,205
Market Cap11.794M
Beta (5Y Monthly)4.56
PE Ratio (TTM)N/A
EPS (TTM)-0.4000
Earnings DateApr 29, 2021 - Apr 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Hemogenyx Pharmaceuticals PLC Announces Conversion of Convertible Loan Notes

      THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

    • ACCESSWIRE

      Hemogenyx Pharmaceuticals PLC Announces Final Results

      LONDON, UK / ACCESSWIRE / April 30, 2021 / THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

    • ACCESSWIRE

      Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

      LONDON, UK / ACCESSWIRE / April 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 30 April 2021 consists of 494,343,020 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 494,343,020.